1-6 of 6
Kimberley Dilley
Close
Sort by
Journal Articles

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2314.
https://doi.org/10.1182/blood-2021-147293
Published: 2021
Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
https://doi.org/10.1182/blood-2020-139705
Published: 2020
Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-139247
Published: 2020
Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3910.
https://doi.org/10.1182/blood-2019-127416
Published: 2019
Journal Articles

Risk Of Solid Subsequent Malignant Neoplasms (SMNs) With Extended Follow-Up Of Childhood Hodgkin Lymphoma (HL) Survivors Is Comparable To The Risk In Known High-Risk Groups Within The General Population: Report From The Late Effects Study Group (LESG)

Smita Bhatia, MD, MPH, Cor van den Bos, MD, PhD, Can-Lan Sun, PhD, Jillian Birch, MD, Lisa Diller, MD, Kimberley Dilley, MD, MPH, FAAP, Jill Ginsberg, Laura Therese Martin, MD, Rajaram Nagarajan, MD, MS, Joseph P. Neglia, MD, MPH, Monica Terenziani, MD, David Tishler, MD, Anna T Meadows, MD, Leslie L. Robison, PhD, MPH, Odile Oberlin, MD, Jennifer P. Berano Teh, MD
Journal: Blood
Blood (2013) 122 (21): 2992.
https://doi.org/10.1182/blood.V122.21.2992.2992
Published: 2013
Journal Articles

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Jeffrey R. Andolina, MD, Kimberley Dilley, MD, MPH
Journal: Blood
Blood (2009) 114 (22): 70.
https://doi.org/10.1182/blood.V114.22.70.70
Published: 2009